Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.

about

A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness.

P2860

Q47617662-0685C96E-0282-488E-8740-52BD0DED59A4

P2860

Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.

Item

http://www.wikidata.org/entity/Q38989642

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Paliperidone for the treatment ...... rs - a drug safety evaluation.

@en

type

Item

label

Paliperidone for the treatment ...... rs - a drug safety evaluation.

@en

prefLabel

Paliperidone for the treatment ...... rs - a drug safety evaluation.

@en

P1476

Paliperidone for the treatment ...... rs - a drug safety evaluation.

@en

P2093

A C Altamura

http://www.w3.org/2001/XMLSchema#string

A Reggiori

http://www.w3.org/2001/XMLSchema#string

C Di Pace

http://www.w3.org/2001/XMLSchema#string

M C Mauri

http://www.w3.org/2001/XMLSchema#string

S Paletta

http://www.w3.org/2001/XMLSchema#string

P2860

How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophrenia

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.

The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

P304

365-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2017.1288716

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28140680

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia

Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.

about

P2860

P2860

Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921